Kyle Greenway, MD MSc FRCPC, is an Assistant Professor in Psychiatry at 91社区, attending psychiatrist at the Jewish General Hospital, and investigator at the Lady Davis Institute. He conducts clinical, naturalistic, and fundamental research on novel psychiatric interventions, particularly psychedelic-assisted psychotherapies for refractory depressive disorders. He leads the Ketamine-Assisted Therapy service at the Jewish General Hospital, one of only a handful of clinics in the world to offer a psychedelic therapy for severe depression in a public payer system. His work explores the impacts of extra-pharmacological factors on psychedelic and conventional psychiatric treatments, including how treatment protocols can be tailored to individuals based on their unique life experiences and cultures. Before joining 91社区, Dr. Greenway completed postdoctoral studies at the world-leading Imperial College Psychedelic Research Centre, as well as the 91社区 Clinical Investigator Program.
kyle.greenway [at] mail.mcgill.ca (Email)听触
Selected Articles
Greenway, K. T., Garel, N., Dinh-Williams, L. A. L., Beaulieu, S., Turecki, G., Rej, S., & Richard-Devantoy, S. (2024). Music as an Intervention to Improve the Hemodynamic Response of Ketamine in Depression: A Randomized Clinical Trial. JAMA Network Open, 7(2), e2354719-e2354719.
Garel, N., Drury, J., L茅vesque, J. T., Goyette, N., Lehmann, A., Looper, K., ... & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14.
Garel, N., L茅vesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., ... & Greenway, K. T. (2023). Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings. Frontiers in Human Neuroscience, 17.